Vaginal dryness at menopause: when it's just estrogen loss, and when it's something else

What most postmenopausal vaginal dryness actually is

If you have vaginal dryness after menopause, you're in very large company. Genitourinary syndrome of menopause (GSM) affects between 27% and 84% of postmenopausal women^{1, 2, 3}.

The most common symptom is vaginal dryness, reported by most women with GSM². Painful sex and itching are also very common². These symptoms cluster together because the underlying tissue changes affect the entire genitourinary system.

GSM is diagnosed clinically based on what you report and what your clinician sees during exam. Sometimes vaginal pH is checked (it tends to rise above 5 when estrogen is low), but this isn't required. GSM is chronic and progressive without treatment, but responds well to vaginal moisturizers, lubricants, and local estrogen therapy.

Why your tissues change after menopause

When estrogen levels drop at menopause, the vaginal lining thins, loses blood flow, and produces less natural lubrication. The tissue becomes less acidic, which increases infection risk¹.

The vaginal epithelium becomes thinner and more fragile. Blood vessels decrease, reducing natural moisture. The pH rises from around 4.5 to above 5. These changes affect the vulva, urethra, and bladder, which is why GSM symptoms often include urinary urgency, recurrent UTIs, and bladder discomfort.

The conditions that look like GSM but aren't

Several other conditions cause vaginal dryness, itching, and pain after menopause but aren't caused by estrogen loss and don't respond to standard GSM treatment. The most important is lichen sclerosus.

Lichen sclerosus is a chronic autoimmune inflammatory skin disease — 87% of cases occur in women over 50. It presents with intense vulvar itching and characteristic white patches on the vulva with a thin, fragile texture often described as resembling cigarette paper³. Over time, it can cause anatomical changes including fusion of the clitoral hood, shrinkage of the labia, and narrowing of the vaginal opening³.

Lichen planus and lichen simplex chronicus are other inflammatory skin conditions that affect the vulva with similar symptoms but different patterns on examination.

Women with lichen sclerosus or erosive lichen planus have significantly higher rates of autoimmune conditions. If you have thyroid disease, vitiligo, alopecia areata, or another autoimmune condition, your risk is higher.

These conditions require different treatment than GSM. Lichen sclerosus is treated with topical corticosteroids, not estrogen.

When to see a clinician

These patterns should prompt clinical evaluation:

Intense itching that dominates the symptom picture. If itching is more prominent than dryness, if it's relentless, if it interferes with sleep or daily life, that's not typical GSM.

Any visible skin changes on the vulva: white patches, thickened areas, ulcers, shiny smooth skin, or a thin fragile texture like tissue paper^{3, 4}.

Symptoms that don't respond to standard GSM treatment after 8–12 weeks. If you've been using vaginal moisturizers regularly and lubricant during sex, or if you've tried local estrogen therapy for several weeks without improvement, something else may be going on^{3, 4}.

Any lesion that is expanding, persistent, pigmented, or irritating. GSM doesn't cause discrete lesions⁴.

Anatomical changes: labial shrinkage, changes around the clitoris or clitoral hood, or progressive narrowing of the vaginal opening³.

These patterns don't mean you have cancer. But they do mean you need an exam by a clinician who can distinguish between GSM and other vulvar conditions.

Why lichen sclerosus specifically matters

Sokkai tracks your cycle and symptoms together, making patterns like this visible over time. See how Sokkai works →

Lichen sclerosus deserves specific attention because untreated disease carries a 5–7% risk of progression to vulvar squamous cell carcinoma³. This risk is reduced with adequate disease control using topical corticosteroids, but not eliminated³.

Lichen sclerosus needs to be diagnosed, treated, and monitored ongoing even when well-controlled. It's a known precursor to vulvar cancer, which is why early detection of precancerous changes matters.

Biopsy is the gold standard when diagnosis is uncertain, when there's concern for neoplastic change, or when treatment isn't working⁴. The threshold for biopsy is intentionally low because the stakes — missing an early vulvar cancer or precancerous change — are high.

When and why you need a biopsy

ACOG guidelines are clear: biopsy is indicated when the diagnosis is uncertain, to rule out premalignant or malignant conditions, or when there's concern for treatment failure⁴. Any persistent vulvar lesion — especially if pigmented, expanding, or not responding to treatment — should be biopsied⁴.

A biopsy is not a sign your clinician thinks you have cancer. It's a diagnostic tool. Many vulvar conditions look similar visually, and histology is the only way to distinguish lichen sclerosus from lichen planus, lichen simplex chronicus, and neoplastic changes⁴.

Early detection of vulvar intraepithelial neoplasia (VIN) — precancerous changes in vulvar tissue — is why the biopsy threshold is low. VIN is highly treatable when caught early.

The procedure is usually done in the office with local anesthetic. Most biopsies show benign conditions — you get a diagnosis and treatment plan.

What this means for you

If you have typical menopausal vaginal dryness — dryness, mild irritation, pain during sex, and no alarming skin changes — start with the standard GSM approach. Use a vaginal moisturizer two to three times per week. Use lubricant during sex. If symptoms persist after a few weeks, talk to your clinician about vaginal estrogen therapy, which is highly effective for GSM.

Give this approach 8–12 weeks to work. The tissue needs time to respond.

If you have intense itching, visible skin changes (especially white patches or texture changes), or symptoms that don't improve with standard GSM treatment, request a full vulvar and vaginal exam.

Don't assume all postmenopausal vulvar symptoms are "just menopause." Most are — but the exceptions matter for cancer prevention. If it's straightforward dryness and pain during sex with no red flags, starting treatment is reasonable. If anything feels atypical — especially intense itching or visible changes — an exam comes first.

If you have a history of autoimmune disease (thyroid conditions, vitiligo, alopecia areata, lupus, rheumatoid arthritis), mention it when you discuss vulvar symptoms. It raises the index of suspicion for lichen sclerosus or lichen planus.

The goal is not to become hypervigilant about every vulvar symptom. The goal is to know when to treat the expected (GSM) and when to escalate for the exceptions. Most postmenopausal vaginal dryness is GSM. When it's not, catching it early makes all the difference.

Vaginal estrogen is not the only prescription option. A systematic review found that vaginal DHEA (prasterone) and ospemifene, a daily pill that acts on vaginal tissue, may also improve some GSM symptoms such as dryness and pain during sex⁵. These may be worth discussing with your clinician if vaginal estrogen doesn't suit you.

What we don't know yet

Research into vulvar conditions after menopause still has significant gaps. We don't fully understand why lichen sclerosus develops or why some women develop it while others don't, despite similar hormonal changes. Individual response to standard GSM treatment varies widely — some women see dramatic improvement with vaginal estrogen while others see minimal change, and we can't yet predict who will respond well. Biopsy thresholds and surveillance protocols for vulvar conditions continue to evolve as we learn more about which lesions carry the highest cancer risk and how frequently monitoring needs to happen. The interaction between GSM and other inflammatory vulvar conditions isn't fully mapped — some women have both, and treatment protocols for managing overlapping conditions are still being refined.

Most studies of hormonal GSM treatments are short, often 12 weeks or less. A systematic review found limited evidence on long-term safety and effectiveness, so the best length of treatment hasn't been formally defined⁵.